Four-year follow up data for Roche's Evrysdi show continued

Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMANinety-one percent of children were...

Related Keywords

London ,City Of ,United Kingdom ,Switzerland ,Japan ,United States ,British ,America ,Loren Kalm ,Kirti Pandey ,Nathalie Altermatt ,Levi Garraway ,Giovanni Baranello ,Roche Group Media Relations ,Drug Administration ,European Medicines Agency ,Office Of Orphan Products Development ,Society For Medicines Research ,Institute Of Child Health Hospital ,Head Of Global Product Development ,Roche Group ,Genentech ,Toddler Development Third Edition ,Research Clinical Care Meeting ,British Pharmacological Society ,Gross Motor Scale ,Bayley Scales ,Hammersmith Infant Neurological Examination ,Clinical Care Meeting ,Ormond Street Institute ,Child Health ,Great Ormond Street Hospital ,Chief Medical Officer ,Global Product ,Orphan Drug Designation ,Drug Discovery ,Medicines Research ,Orphan Products Development ,Drug Designation ,Muscular Atrophy ,Spinal Muscular Atrophy ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Swiss Stock Exchange Ro ,F Hoffmann La Roche Ltd ,